KLRK1 and neoplasm: The MSCs-treated groups had the most tumor-associated neutrophils (∼35%) whereas MSC1-treated groups had more monocytes (∼40%) and MSC2-treated groups had close to equivalent numbers of neutrophils, monocytes and lymphocytes (∼20%/each) based on differential flow cytometry analyses with specific antibodies to CD3, CD4, CD8, CD11b, CD45R, Ly-6G (Gr-1), and NKG2D (CD314) (http://phenome.jax.org/db/q?rtn=projects/docstatic&doc=Jaxpheno6/Jaxpheno6_Protocol).